Sintilimab plus chemo and radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV esophageal cancer that has spread to other parts of the body.
- Your cancer is the squamous cell type, which is a common kind of esophageal cancer.
- You are in fairly good health (able to do daily activities and light work).
- Your blood counts, liver, and kidney function are within certain safe limits.
- You do not have an active autoimmune disease, uncontrolled heart problems, or a history of bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests different doses of radiation therapy combined with the immunotherapy drug sintilimab for people with locally advanced esophageal squamous cell carcinoma. The goal is to find the best radiation dose to improve treatment outcomes.
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
Hear when a new Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.